Zetia: Targeted Cholesterol Management for Lower LDL
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.71 | $51.21 (0%) | 🛒 Add to cart |
| 60 | $1.37 | $102.41 $82.33 (20%) | 🛒 Add to cart |
| 90 | $1.26 | $153.62 $113.46 (26%) | 🛒 Add to cart |
| 120 | $1.21 | $204.82 $145.58 (29%) | 🛒 Add to cart |
| 180 | $1.15 | $307.23 $207.84 (32%) | 🛒 Add to cart |
| 270 | $1.12 | $460.85 $302.21 (34%) | 🛒 Add to cart |
| 360 | $1.10
Best per pill | $614.47 $395.59 (36%) | 🛒 Add to cart |
Synonyms | |||
Zetia (ezetimibe) represents a significant advancement in the management of high cholesterol, offering a targeted mechanism of action distinct from statins. As a selective cholesterol absorption inhibitor, it works directly in the digestive system to reduce the amount of cholesterol the body absorbs from food. This monograph provides a comprehensive, expert-level overview of Zetia, detailing its pharmacology, clinical applications, and practical considerations for healthcare providers and informed patients. It is designed for use as an adjunct to diet and exercise, particularly when statin therapy alone is insufficient or not tolerated.
Features
- Active Ingredient: Ezetimibe 10 mg
- Pharmacologic Class: Selective Cholesterol Absorption Inhibitor
- Mechanism of Action: Acts at the brush border of the small intestine to inhibit the absorption of dietary and biliary cholesterol
- Administration: Oral tablet
- Bioavailability: Not significantly affected by food
- Time to Peak Plasma Concentration: 4-12 hours
- Half-life: Approximately 22 hours
- Protein Binding: >90% to plasma proteins
- Metabolism: Primarily glucuronidation in the small intestine and liver
- Excretion: Primarily fecal (78%) with minimal renal excretion (11%)
Benefits
- Targeted LDL-C Reduction: Provides an average additional 18-25% reduction in LDL cholesterol when added to a stable statin regimen, offering a dual-inhibition approach.
- Non-Statin Option: Offers a valuable therapeutic pathway for patients who are statin-intolerant, providing effective cholesterol management through a different mechanism.
- Favorable Safety Profile: Generally well-tolerated with a low incidence of muscle-related adverse events, a common concern with some statin therapies.
- Complementary Action: Can be effectively combined with statins to achieve synergistic LDL-lowering effects, helping more patients reach their guideline-directed lipid goals.
- Improves Other Lipid Parameters: Modestly reduces triglycerides and increases HDL cholesterol, contributing to a more comprehensive lipid management strategy.
- Convenient Dosing: Simple once-daily oral administration supports long-term adherence to therapy.
Common use
Zetia is indicated as an adjunct to diet for the reduction of elevated total cholesterol, LDL cholesterol, and apolipoprotein B in patients with primary hyperlipidemia, either alone or in combination with an HMG-CoA reductase inhibitor (statin). It is also indicated for the reduction of elevated sitosterol and campesterol in patients with homozygous sitosterolemia (phytosterolemia). In clinical practice, it is most commonly used in two scenarios: as add-on therapy for patients on a statin who have not achieved their LDL-C goal, and as monotherapy for patients who are intolerant of statins. Its use is supported by major cardiovascular guidelines, which recognize the value of non-statin therapies for further risk reduction.
Dosage and direction
The recommended dosage of Zetia is 10 mg taken orally once daily, with or without food. It can be administered at any time of day, though consistency is recommended to maintain stable plasma levels. When used in combination with a statin, Zetia may be administered concurrently with the statin dose. For patients also taking bile acid sequestrants (e.g., cholestyramine), Zetia should be taken at least 2 hours before or 4 hours after the bile acid sequestrant to avoid significantly reduced absorption of ezetimibe. No dosage adjustment is necessary for elderly patients or those with mild hepatic impairment. Adherence to a standard cholesterol-lowering diet should continue during treatment.
Precautions
Prior to initiating Zetia, secondary causes of hyperlipidemia (e.g., hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be ruled out. Liver function tests should be performed at initiation and periodically thereafter, as recommended by clinical guidelines. Use with caution in patients with moderate or severe hepatic impairment, as the effects and safety in these populations are not well-established. While myopathy and rhabdomyolysis have been reported rarely with Zetia monotherapy, the risk increases when co-administered with a statin. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Zetia is not recommended during pregnancy unless clearly needed, as cholesterol and products of cholesterol biosynthesis are essential for fetal development.
Contraindications
Zetia is contraindicated in patients with a known hypersensitivity to any component of the formulation. The combination of Zetia with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminases. Concomitant use of Zetia with fibrates (other than fenofibrate) is not recommended due to an increased risk of cholelithiasis, as observed in preclinical studies. The safety of combining Zetia with fibrates has not been established in clinical outcomes trials.
Possible side effect
The majority of adverse reactions reported with Zetia are mild and transient. In clinical trials, the most commonly reported side effects for Zetia monotherapy (incidence ≥2% and greater than placebo) included:
- Upper respiratory tract infection
- Diarrhea
- Arthralgia
- Sinusitis
- Pain in extremity
- Fatigue
When used in combination with a statin, common adverse reactions also included:
- Headache
- Myalgia
- Back pain
- Influenza
- Pharyngolaryngeal pain
Serious but less common side effects can include myopathy/rhabdomyolysis, hepatitis, pancreatitis, and elevations in hepatic transaminases. Hypersensitivity reactions, including angioedema and rash, have been reported.
Drug interaction
Zetia has a low potential for drug-drug interactions due to its minimal metabolism via cytochrome P450 enzymes. However, several important interactions exist:
- Bile Acid Sequestrants (e.g., cholestyramine): Co-administration significantly decreases the absorption and bioavailability of ezetimibe. Dosing should be separated by at least 2 hours before or 4 hours after.
- Fibrates (e.g., gemfibrozil, fenofibrate): Concomitant use increases the concentration of ezetimibe. Use with fenofibrate is permitted, but the combination with gemfibrozil is not recommended due to an increased risk of cholesterol gallstones.
- Cyclosporine: Significantly increases ezetimibe concentrations. Use caution and monitor for adverse effects in transplant patients receiving cyclosporine.
- Statins: No clinically significant pharmacokinetic interactions have been observed with various statins (atorvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, rosuvastatin).
Missed dose
If a dose of Zetia is missed, the patient should take it as soon as they remember, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one.
Overdose
There is limited experience with Zetia overdose in humans. In clinical trials, administration of ezetimibe 50 mg/day to healthy volunteers for 14 days was generally well-tolerated. In the event of an overdose, symptomatic and supportive measures should be taken. Due to the extensive protein binding of ezetimibe, hemodialysis is not expected to be effective.
Storage
Zetia tablets should be stored at room temperature, between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep the bottle tightly closed and protect from moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the bottle.
Disclaimer
This information is for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The content has been compiled from available scientific literature but may not encompass all available information.
Reviews
Clinical trials and post-marketing experience have established Zetia as a valuable agent in the lipid-lowering arsenal. The IMPROVE-IT trial, a large outcomes study, demonstrated that adding ezetimibe to simvastatin therapy in patients post-acute coronary syndrome resulted in a significant incremental reduction in LDL-C and a corresponding reduction in major adverse cardiovascular events compared to simvastatin monotherapy. This provided evidence for the cardiovascular benefit of non-statin LDL-lowering. In practice, clinicians value its predictable LDL-lowering efficacy, its utility in statin-intolerant patients, and its generally favorable side effect profile. Patient reviews often highlight its ease of use and the fact that it provides an effective option for those who cannot tolerate higher statin doses.